Formulates pharmaceutical products, including antibiotics, cardiovascular drugs, and anti-cancer therapies. Now — the numbers.
This is an established company with proven profits.
Average growth of 23% a year over the last 3 years. Every year shown ended in profit.
The gap is $14.4M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 23% a year on average.
The stock sits at $0.0003. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 3.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.